OncoAssure

Executive Summary

OncoAssure is a Dublin-based private diagnostics company developing proprietary biomarkers to improve cancer management. Its lead product is a post-biopsy prognostic test for prostate cancer, designed to identify patients with low-risk disease who can safely avoid aggressive treatments. The technology leverages prior work from OncoMark Ltd., developer of the CE-marked OncoMasTR breast cancer test. While the company has not disclosed funding or clinical milestones publicly, its focus on addressing overtreatment in prostate cancer aligns with a growing clinical need. The company operates in the competitive molecular diagnostics space but differentiates with a test intended to stratify patients after initial biopsy. Given the lack of recent public updates, the company appears to be in early-stage development or seeking commercial partnerships.

Upcoming Catalysts (preview)

• TBDClinical validation study results for prostate cancer prognostic test50% success
• TBDRegulatory submission or clearance (e.g., CE marking or FDA) for lead test30% success
• TBDPartnership or licensing deal with larger diagnostics or pharma company40% success